The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of 200 mg PO BIW). We recently highlighted encequidar, a P-gp…
Drug Hunter
Drug Hunter
The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of 200 mg PO BIW). We recently highlighted encequidar, a P-gp…